S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
Average 126% gains – NO losers!?   (Ad)pixel
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Average 126% gains – NO losers!?   (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
Climate bill: Could coal communities shift to nuclear?
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
Average 126% gains – NO losers!?   (Ad)pixel
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Average 126% gains – NO losers!?   (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
Climate bill: Could coal communities shift to nuclear?
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
Average 126% gains – NO losers!?   (Ad)pixel
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Average 126% gains – NO losers!?   (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
Climate bill: Could coal communities shift to nuclear?
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
2 Important Retail Stock Battles to Watch
Average 126% gains – NO losers!?   (Ad)pixel
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Average 126% gains – NO losers!?   (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
Climate bill: Could coal communities shift to nuclear?
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
NASDAQ:ADAP

Adaptimmune Therapeutics - ADAP Earnings Date, Estimates & Call Transcripts

$2.38
+0.13 (+5.78%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.27
$2.54
50-Day Range
$1.48
$2.38
52-Week Range
$1.26
$6.86
Volume
567,635 shs
Average Volume
224,308 shs
Market Capitalization
$385.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50

Earnings Summary

Upcoming
Earnings Date
Nov. 3Estimated
Actual EPS
(May. 9)
-$0.32 Missed By -$0.06
Consensus EPS
(May. 9)
-$0.26
Last Year's Q2 EPS
(5/5/2021)
-$0.24
Skip Charts & View Estimated and Actual Earnings Data

ADAP Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ADAP Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Adaptimmune Therapeutics Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20221($0.25)($0.25)($0.25)
Q2 20221($0.21)($0.21)($0.21)
Q3 20221($0.22)($0.22)($0.22)
Q4 20221($0.23)($0.23)($0.23)
FY 20224($0.91)($0.91)($0.91)

ADAP Earnings Date and Information

Adaptimmune Therapeutics last released its quarterly earnings data on May 9th, 2022. The biotechnology company reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by $0.06. The business earned $3.58 million during the quarter, compared to analyst estimates of $4 million. Adaptimmune Therapeutics has generated ($1.12) earnings per share over the last year (($1.12) diluted earnings per share). Earnings for Adaptimmune Therapeutics are expected to grow in the coming year, from ($1.15) to ($1.02) per share. Adaptimmune Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 3rd, 2022 based off prior year's report dates.

Adaptimmune Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
11/3/2022
(Estimated)
        
5/9/2022Q1 2022($0.26)($0.32)($0.06)($0.32)$4.00 million$3.58 million    
3/14/2022Q4 2021($0.22)($0.25)($0.03)($0.25)$80.25 million$1.42 million    
11/4/20219/30/2021($0.26)($0.30)($0.04)($0.27)$1.20 million$1.20 million    
8/8/20216/30/2021($0.25)($0.24)+$0.01($0.24)$0.60 million$3.10 million    
5/5/20213/31/2021($0.25)($0.24)+$0.01($0.24)$0.75 million$0.43 million  
2/24/202112/31/2020($0.23)($0.24)($0.01)($0.24)$1.20 million$1.50 million  
11/10/20209/30/2020($0.25)($0.24)+$0.01($0.23)$1.20 million$1.19 million  
8/6/20206/30/2020($0.24)($0.24)($0.24)$0.95 million$0.50 million  
5/14/2020Q1($0.25)($0.24)+$0.01($0.24)$25.90 million$0.76 million  
2/27/2020Q4 2019($0.33)($0.28)+$0.05($0.28)$3.60 million$0.73 million
11/6/2019Q3($0.33)($0.36)($0.03)($0.37)$7.00 million$0.24 million  
8/1/2019Q2 2019($0.35)($0.42)($0.07)($0.42)$4.25 million$0.16 million  
5/6/2019Q1 2019($0.28)($0.24)+$0.04($0.24)$1.50 million
2/27/2019Q4 2018($0.29)($0.36)($0.07)($0.36)$14.50 million$1.48 million
11/6/20189/30/2018($0.03)$0.06+$0.09$0.05$29.41 million$40.79 million
8/2/20186/30/2018($0.28)($0.48)($0.20)($0.48)$7.76 million$9.04 million
5/9/2018Q1 2018($0.24)($0.04)+$0.20($0.24)$7.59 million$8.20 million
3/15/2018Q4 2017($0.25)($0.29)($0.04)($0.29)$9.38 million$4.27 million
8/3/20176/30/2017($0.24)($0.24)($0.24)$5.43 million$3.52 million
5/10/20173/31/2017($0.24)($0.30)($0.06)($0.30)$5.07 million$2.86 million
3/13/201712/31/2016($0.27)($0.22)+$0.05($0.22)$3.98 million$8.54 million
11/10/2016Q3 2016($0.27)($0.24)+$0.03($0.24)$6.08 million$2.42 million
8/8/2016Q2 2016($0.22)($0.31)($0.09)($0.31)$4.75 million$0.33 million
5/12/2016Q1 2016($0.22)($0.04)+$0.18($0.04)$7.11 million$2.92 million
3/17/2016Q4 2015($0.14)($0.13)+$0.01($0.13)$2.00 million$4.18 million
11/13/2015Q3 2015($0.23)($0.02)+$0.21($0.02)$3.93 million












Adaptimmune Therapeutics Earnings - Frequently Asked Questions

When is Adaptimmune Therapeutics's earnings date?

Adaptimmune Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 3rd, 2022 based off last year's report dates. Learn more on ADAP's earnings history.

Did Adaptimmune Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Adaptimmune Therapeutics (NASDAQ:ADAP) missed the analysts' consensus estimate of ($0.26) by $0.06 with a reported earnings per share (EPS) of ($0.32). Learn more on analysts' earnings estimate vs. ADAP's actual earnings.

How can I listen to Adaptimmune Therapeutics's earnings conference call?

The conference call for Adaptimmune Therapeutics's latest earnings report can be listened to online. Listen to Conference Call

How can I read Adaptimmune Therapeutics's conference call transcript?

The conference call transcript for Adaptimmune Therapeutics's latest earnings report can be read online. Read Transcript

How much revenue does Adaptimmune Therapeutics generate each year?

Adaptimmune Therapeutics (NASDAQ:ADAP) has a recorded annual revenue of $6.15 million.

How much profit does Adaptimmune Therapeutics generate each year?

Adaptimmune Therapeutics (NASDAQ:ADAP) has a recorded net income of -$158.09 million. ADAP has generated -$1.12 earnings per share over the last four quarters.

What is Adaptimmune Therapeutics's EPS forecast for next year?

Adaptimmune Therapeutics's earnings are expected to grow from ($1.15) per share to ($1.02) per share in the next year.

More Earnings Resources from MarketBeat

Upcoming Earnings:
This page (NASDAQ:ADAP) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.